Premium
Efficacy of the subcutaneous reformulated triptorelin depot in children with central precocious puberty
Author(s) -
Partsch CJ,
Büren E,
Brand M,
Heger S,
Sippell WG
Publication year - 1998
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1998.tb00944.x
Subject(s) - triptorelin , medicine , bone age , luteinizing hormone , precocious puberty , bone maturation , basal (medicine) , leuprorelin , follicle stimulating hormone , hormone , endocrinology , urology , gonadotropin releasing hormone , insulin
The efficacy, safety and acceptance of newly formulated triptorelin s.c. (Decapeptyl ® Depot, DDsc) was compared to triptorelin i.m. (DDim) in seven children with central precocious puberty (CPP) in a prospective study. Both formulations were given for 6 months consecutively. During both treatment periods suppression of basal and gonadotropin‐releasing hormone (GnRH)‐stimulated levels of luteinizing hormone and follicle‐stimulating hormone, suppression of sex steroids, arrest of the maturation of gonads and uterus, and slowing of bone maturation were achieved. The height standard deviation score for bone age increased significantly during DDsc treatment (‐1.33 ± 0.90 to 1.07 ± 0.92, p < 0:05). The ratio bone age/chronological age decreased significantly during both treatment periods (1.25 ± 0.24 to 1.20 ± 0.23, p < 0:05, and 1.20 ± 0.23 to 1.16 ± 0.22, p < 0:05). With the injection of DDsc in the abdominal wall, a palpable, non‐irritating resistance which gradually decreased in size occurred in one patient. With injection into the thigh no indurations were seen. No allergic reactions were encountered. Five of the patients considered DDsc therapy as more pleasant and described a definite decrease in fear of injections. All parents considered DDsc treatment as equal or better than DDim in respect to the suppression of their child's puberty. It was concluded that DDsc is equipotent to DDim in the treatment of CPP. For the majority of patients DDsc was more acceptable than DDim. The thigh is recommended for the subcutaneous application of DD.